Brokers Issue Forecasts for IceCure Medical FY2025 Earnings

Key Points

• Brookline Capital Management has downgraded its FY2025 earnings estimate for IceCure Medical to ($0.20) per share, from a previous estimate of ($0.17), while maintaining a "Buy" rating on the stock.
• IceCure Medical reported quarterly earnings of $0.06 per share, exceeding the consensus estimate of ($0.06) by $0.12, although its revenue fell short of expectations at $0.66 million.
• Shares of IceCure Medical have a current market price of $0.90, with a recent price target of $2.77 set by Loop Capital, while HC Wainwright has lowered their price target from $2.50 to $2.00.

IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) - Equities research analysts at Brookline Capital Management lowered their FY2025 earnings per share (EPS) estimates for shares of IceCure Medical in a research note issued to investors on Wednesday, August 13th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.20) per share for the year, down from their prior estimate of ($0.17). Brookline Capital Management has a "Buy" rating on the stock. The consensus estimate for IceCure Medical's current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical's FY2027 earnings at $0.08 EPS.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.12. The business had revenue of $0.66 million during the quarter, compared to the consensus estimate of $0.90 million. IceCure Medical had a negative return on equity of 136.96% and a negative net margin of 317.62%.

A number of other research firms also recently issued reports on ICCM. Zacks Research downgraded IceCure Medical from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. Wall Street Zen lowered shares of IceCure Medical from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. HC Wainwright decreased their price objective on shares of IceCure Medical from $2.50 to $2.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Finally, Loop Capital set a $2.77 price objective on shares of IceCure Medical in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $2.39.

IceCure Medical Stock Up 0.8%

ICCM stock traded up $0.0072 during mid-day trading on Monday, reaching $0.8828. 364,139 shares of the company traded hands, compared to its average volume of 2,783,709. The stock has a market cap of $51.82 million, a price-to-earnings ratio of -5.52 and a beta of 0.32. The company has a quick ratio of 0.88, a current ratio of 1.18 and a debt-to-equity ratio of 0.02. IceCure Medical has a fifty-two week low of $0.48 and a fifty-two week high of $1.66. The firm's 50 day moving average price is $0.97 and its 200 day moving average price is $1.11.

Hedge Funds Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC raised its holdings in IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 58.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,453 shares of the company's stock after purchasing an additional 14,893 shares during the period. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. Institutional investors own 0.62% of the company's stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.